Cancer care and research
Practice-changing oncology and hematology research, from early detection through survivorship.
Oncology
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.
Rayan Salih · September 24, 2026 · 6 min
Oncology
FDA accelerated approval makes tumor HER2 kinase-domain mutation status treatment-defining for eligible adults with previously treated, advanced nonsquamous NSCLC.
Rayan Salih · 7 min read
Oncology
MATTERHORN found better event-free survival and pathologic response with perioperative durvalumab plus FLOT for resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Oncology
Interim phase 3 results favor adding sacituzumab tirumotecan to first-line pembrolizumab for PD-L1-positive advanced NSCLC, but survival, safety and generalizability remain unsettled.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval applies to previously treated, advanced non-squamous NSCLC with qualifying activating mutations in the HER2 tyrosine kinase domain—not every ERBB2 alteration.
Rayan Salih · 6 min read
Oncology
The FDA approved an allogeneic regulatory T-cell therapy for adults with hematologic malignancies undergoing matched-donor stem cell transplantation. Programs must assess eligibility, logistics and safety readiness.
Rayan Salih · 6 min read
Oncology
Ivonescimab plus chemotherapy prolonged median overall survival after EGFR-TKI therapy, but toxicity, generalizability and US regulatory status shape its relevance.
Rayan Salih · 7 min read
Oncology
The FDA granted accelerated approval to sevabertinib for adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine kinase domain mutations, making validated genomic identification central to treatment selection.
Rayan Salih · 6 min read
Oncology
Accelerated approval places zidesamtinib after a prior ROS1 tyrosine kinase inhibitor, with reported activity in systemic and intracranial disease but no randomized evidence yet.
Rayan Salih · 6 min read
Oncology
FDA approval of rusfertide creates a systemic option for adults with polycythemia vera whose erythrocytosis has traditionally required phlebotomy, with or without cytoreductive therapy.
Dr. Abu Bakar · 6 min read
Oncology
FDA approval makes vepdegestrant an option for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy.
Dr. Abu Bakar · 6 min read
Oncology
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma after systemic therapy or when multi-agent therapy is not feasible.
Rayan Salih · 6 min read
Oncology
The FDA approved gedatolisib plus fulvestrant, with or without palbociclib, after endocrine therapy progression in PIK3CA-wild-type HR-positive, HER2-negative advanced breast cancer.
Rayan Salih · 6 min read
Oncology
In China’s phase 3 HARMONi-6 trial, ivonescimab plus chemotherapy improved interim overall survival versus tislelizumab plus chemotherapy in advanced squamous NSCLC.
Rayan Salih · 6 min read
Oncology
A meta-analysis found invasive disease-free survival gains with adjuvant abemaciclib and ribociclib, but not palbociclib, in HR-positive, HER2-negative early breast cancer.
Rayan Salih · 7 min read
Oncology
The accelerated approval covers eligible adults with previously treated multiple myeloma after exposure to both a proteasome inhibitor and an immunomodulatory agent.
Rayan Salih · 6 min read
Oncology
The FDA authorized two zanidatamab-based first-line strategies for unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Rayan Salih · 6 min read
Oncology
The FDA granted accelerated approval to vusolimogene oderparepvec plus nivolumab for unresectable advanced melanoma progressing after PD-1 therapy, based on tumor response and response durability.
Dr. Abu Bakar · 6 min read
Oncology
In ENDURANCE, indefinite lenalidomide maintenance did not improve 7-year overall survival versus a fixed 2-year course for standard-risk myeloma managed without upfront transplant.
Rayan Salih · 6 min read
Oncology
Traditional approval makes selpercatinib an established tumor-agnostic option for qualifying RET fusion-positive advanced solid tumors in adults and children age 2 years and older.
Rayan Salih · 7 min read
Oncology
Median overall survival was reported at 13.2 months with daraxonrasib versus 6.6 months with chemotherapy in KRAS-mutant metastatic pancreatic cancer, but comparative uncertainty limits practice implications.
Rayan Salih · 7 min read
Oncology
The FDA has moved lutetium Lu-177 vipivotide tetraxetan into PSMA-positive metastatic hormone-sensitive prostate cancer when combined with an androgen receptor pathway inhibitor.
Dr. Abu Bakar · 7 min read
Oncology
The FDA expanded enfortumab vedotin plus pembrolizumab around cystectomy to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility.
Rayan Salih · 7 min read
Oncology
Perioperative enfortumab vedotin plus pembrolizumab improved survival and pathologic complete response versus cisplatin–gemcitabine in cisplatin-eligible adults undergoing cystectomy.
Rayan Salih · 7 min read
Oncology
A phase 3 trial found that daily ensartinib substantially prolonged disease-free survival after chemotherapy and complete resection of stage IB-IIIB ALK-positive NSCLC.
Dr. Abu Bakar · 6 min read
Oncology
Over the past two decades, colorectal cancer (CRC) epidemiology has undergone a dramatic shift.
Rayan Salih · 7 min read
Oncology
While mortality rates for most major solid tumors, including breast, lung, and colorectal cancers, have steadily declined over
Rayan Salih · 8 min read
Oncology
A diagnosis of cancer during adolescence or young adulthood disrupts life at a pivotal developmental crossroads.
Rayan Salih · 9 min read
Oncology
The metabolic landscape of oncology is rapidly evolving, driven by an expanding understanding of how systemic metabolic dysfunction
Rayan Salih · 8 min read
Oncology
The clinical management of mantle cell lymphoma (MCL) represents one of the most persistent challenges in aggressive B-cell
Rayan Salih · 7 min read
Oncology
For oncologists, otolaryngologists, and clinical trialists treating high-risk, locally advanced squamous cell carcinoma of the head and neck
Rayan Salih · 7 min read
Oncology
For healthcare providers managing cutaneous malignancies, Merkel Cell Carcinoma (MCC) has long represented one of the most formidable
Rayan Salih · 9 min read
Oncology
For decades, the oncology landscape has viewed lifestyle modification as a pleasant, well-intentioned afterthought—a supportive measure for general
Rayan Salih · 10 min read
Oncology
For decades, hematologists treating relapsed or refractory (R/R) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) have
Rayan Salih · 10 min read
Oncology
For years, thoracic oncologists faced a frustrating therapeutic ceiling when treating non-small cell lung cancer (NSCLC) driven by
Rayan Salih · 10 min read
Oncology
In NSCLC there has been a therapeutic revolution in the management of patients with advanced stage disease, by
Rayan Salih · 10 min read
Oncology
From Late to Early Intervention: Advanced Prostate Cancer Treatment.
Rayan Salih · 9 min read
Oncology
The therapeutic landscape for oncogene-addicted non-small cell lung cancer (NSCLC) has shifted dramatically over the past decade.
Rayan Salih · 8 min read
Oncology
For years, oncology providers have recognized that metastatic colorectal cancer (mCRC) is not a monolithic disease.
Rayan Salih · 9 min read
Oncology
The landscape of advanced oncology is undergoing an unprecedented structural transition.
Rayan Salih · 9 min read
One story a day
One health journey each morning — no advice, no alarm, just company for the road.
